0000000000218984

AUTHOR

Bojko Bjelakovic

showing 4 related works from this author

Prevalence of left ventricular hypertrophy in children and young people with primary hypertension: Meta-analysis and meta-regression

2022

BackgroundLeft ventricular hypertrophy (LVH) is the main marker of HMOD in children and young people (CYP). We aimed to assess the prevalence of LVH and its determinants in CYP with primary hypertension (PH).MethodsA meta-analysis of prevalence was performed. A literature search of articles reporting LVH in CYP with PH was conducted in Medline, Embase, and Cochrane databases. Studies with a primary focus on CYP (up to 21 years) with PH were included. Meta-regression was used to analyze factors explaining observed heterogeneity.ResultsThe search yielded a total of 2,200 articles, 153 of those underwent full-text review, and 47 reports were included. The reports evaluated 51 study cohorts inc…

left ventricular hypertrophy ; primary hypertension ; children ; adolescents ; left ventricular mass indexJovesHypertensionHipertensióPressió sanguíniaCardiology and Cardiovascular MedicineInfantsChildren
researchProduct

Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

2023

Non-Alcoholic Fatty Liver Disease (NAFLD) is a common condition affecting around 10–25% of the general adult population, 15% of children, and even > 50% of individuals who have type 2 diabetes mellitus. It is a major cause of liver-related morbidity, and cardiovascular (CV) mortality is a common cause of death. In addition to being the initial step of irreversible alterations of the liver parenchyma causing cirrhosis, about 1/6 of those who develop NASH are at risk also developing CV disease (CVD). More recently the acronym MAFLD (Metabolic Associated Fatty Liver Disease) has been preferred by many European and US specialists, providing a clearer message on the metabolic etiology of the dis…

PharmacologySettore MED/04 - Patologia GeneraleNAFLDLiver steatosisPosition paperDietary supplements; Liver steatosis; NAFLD; Nutraceuticals; Position paper;NutraceuticalsDietary supplements
researchProduct

Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP)

2020

Abstract Acute and chronic physical exercises may enhance the development of statin-related myopathy. In this context, the recent (2019) guidelines of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) for the management of dyslipidemias recommend that, although individuals with dyslipidemia should be advised to engage in regular moderate physical exercise (for at least 30 min daily), physicians should be alerted with regard to myopathy and creatine kinase (CK) elevation in statin-treated sport athletes. However it is worth emphasizing that abovementioned guidelines, previous and recent ESC/EAS consensus papers on adverse effects of statin therapy as wel…

0301 basic medicinemedicine.medical_specialtyConsensusSports medicineContext (language use)Physical exercise03 medical and health sciences0302 clinical medicineAthlethsMuscular DiseasesStatin intoleranceMedicineHumansAdverse effectAthlethExerciseMylagiaDyslipidemiasPharmacologybiologybusiness.industryAthletesExercisesAthleths Exercises Management Mylagia Statin intolerance.Athleths; Exercises; Management; Mylagia; Statin intolerancemedicine.diseasebiology.organism_classificationManagement030104 developmental biologyAthletes030220 oncology & carcinogenesisPhysical therapyPosition paperStatin therapyHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemia
researchProduct

Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases - A position paper from the Internationa…

2021

Inflammation is a marker of arterial disease stemming from cholesterol-dependent to -independent molecular mechanisms. In recent years, the role of inflammation in atherogenesis has been underpinned by pharmacological approaches targeting systemic inflammation that have led to a significant reduction in cardiovascular disease (CVD) risk. Although the use of nutraceuticals to prevent CVD has largely focused on lipid-lowering (e.g, red-yeast rice and omega-3 fatty acids), there is growing interest and need, especially now in the time of coronavirus pandemic, in the use of nutraceuticals to reduce inflammatory markers, and potentially the inflammatory CVD burden, however, there is still not en…

RMArterial diseaseAnti-Inflammatory AgentsInflammationDiseaseC-reactive protein ; cardiovascular disease ; inflammation ; nutraceuticals ; omega-3 ; position paper ; red-yeast rice030204 cardiovascular system & hematologyBioinformaticsSystemic inflammationC-reactive protein03 medical and health sciences0302 clinical medicineNutraceuticalMedicineHumansPosition paper030212 general & internal medicineUncategorizedOmega-3InflammationbiologyC-reactive protein; Cardiovascular disease; Inflammation; Nutraceuticals; Omega-3; Position paper; Red-yeast rice; Anti-Inflammatory Agents; Biomarkers; Cardiovascular Diseases; Humans; Inflammation; Lipids; Dietary SupplementsVascular inflammationbusiness.industryC-reactive proteinC-reactive protein Cardiovascular disease Inflammation Nutraceuticals Omega-3 Position paper Red-yeast rice Anti-Inflammatory Agents Biomarkers Cardiovascular Diseases Humans Inflammation Lipids Dietary SupplementsCardiovascular diseaseRed-yeast riceLipidsCardiovascular DiseasesDietary Supplementsbiology.proteinPosition paperNutraceuticalsNutraceuticalmedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersProgress in cardiovascular diseases
researchProduct